Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 69
GLP-1 drugs, menstrual changes: FAERS 2026
A July 2026 FAERS study found semaglutide carries broader menstrual signals than tirzepatide or liraglutide, but the data cannot establish causation.
How GLP-1 guides bone marrow stem cells
A July 2026 study shows GLP-1 steers bone marrow stem cells toward bone via HIF-2 and AKT, protecting bone in glucocorticoid-treated mice.
GLP-1 drugs and US military adherence
A Military Health System study of 10,649 service members found tirzepatide led on adherence and persistence. Male members discontinued more often than females.
GLP-1 drugs and older adults: key evidence
A 2026 review covers tirzepatide, semaglutide, and liraglutide in older patients with obesity and type 2 diabetes, and where evidence has gaps.
MASLD: semaglutide and resmetirom explained
Two drugs now carry FDA approval for MASH. Here is what the phase 3 trial data says about each and where the evidence gaps remain.
GLP-1 drugs: psychiatric safety in 2026
Tirzepatide and semaglutide show comparable psychiatric profiles. Semaglutide beats older GLP-1 agents on depression and anxiety.
GLP-1 and bone loss from glucocorticoids
A July 2026 Stem Cell Reports paper shows GLP-1 shifts bone marrow stem cells toward bone via HIF-2alpha and AKT signaling in steroid-induced osteoporosis.
GLP-1 Drugs and Menstrual Changes
A 2026 FAERS study found semaglutide and tirzepatide linked to menstrual adverse events in females aged 12-55, adding a new dimension to GLP-1 counseling.
GLP-1 persistence in the US military
A 10,649-patient Military Health System database study found tirzepatide had 81.9% one-year persistence vs 70.7% for semaglutide and 34.2% for liraglutide.
GLP-1 Agonists in Older Adults: Key Issues
Sarcopenia, polypharmacy, and limited age-specific data shape GLP-1 receptor agonist use in older adults with obesity and type 2 diabetes.
MASH drugs: resmetirom and semaglutide
Resmetirom and semaglutide now hold conditional approvals for MASH. Here is what the trial evidence shows and where gaps remain.
Real-world semaglutide: dose and dropout
A Danish study of 206 patients found 38% permanently stopped semaglutide within 12 months; 70% of continuers used doses below the 2.4 mg approved maximum.